Endo, NuPathe, Teva deal

NuPathe said that Teva made an unsolicited cash offer to acquire the specialty pharma for $3.65 per share in cash up front, or about $114.4 million, based on 31.3 million shares outstanding as of Nov. 11, 2013. The upfront price is a 59% premium to NuPathe's close of $2.30 on Dec. 13, 2013, before the company said it will be acquired by Endo for $2.85 per share in cash up front. Teva's bid is a 28% premium to Endo's (see BioCentury, Dec. 23, 2013). ...